Bavarian Nordic — September 2021
-
Zea - GS har vel blot fået forelagt fakta samt ledelsens vurderinger og set, at vi er på rette vej. De kan jo bare læse med på PI, hvis de vil vide mere. Mini-Novo er ved at blomstre.
-
@Sponsor - du skal bare drukne sorgerne eller fejre succeserne. R
-
Wrong place
-
-
@janolsen - tak for super artikel
-
-
Korte positioner ultimo august: https://www.proinvestor.com/?p=debat_1&postid=96802&thread=50&start=
-
Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models – in Contrast to Short-acting GLP-2
Company announcement – No. 59/ 2021 Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide...
GlobeNewswire News Room (www.globenewswire.com)
-
“We are excited about the clinical progress of glepaglutide, currently in Phase 3 clinical trials for the treatment of SBS, and we are proud to present new research on the program at ESPEN 2021,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “SBS is a debilitating condition where parenteral support is often needed for patient survival.
-
The data presented at ESPEN demonstrate the attractive profile of glepaglutide following once-weekly dosing in humans and the dose-dependent effects on both small and large intestines in animals, underscoring its differentiation as a potential treatment option for SBS.”
men tak 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind